Answers are grounded in this paper and cite their sources.
Demonstrates a bispecific mini-antibody's ability to regulate TNF in human monocytes, suggesting a new therapeutic approach for inflammatory diseases.
Systemic blockade of proinflammatory cytokines such as IL-1, TNF, and IL-6 using therapeutic antibodies has proven effective in treating a wide range of autoimmune and other chronic inflammatory diseases. However, such blockade also suppresses non-redundant protective and homeostatic functions of cytokines, leading to a number of undesirable side effects. In this study, a novel bispecific mini-antibody featuring modules targeting human TNF and CD14 demonstrated efficacy in controlling TNF secretion from human peripheral blood monocytes. Administration of this antibody protected humanized TNF mice from lethal hepatotoxicity induced by a combination of LPS and D-galactosamine.
No takes yet. Share an insight, caveat, or question.
Konev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: